For a listing of other research studies recruiting patients please visit our Active Studies page.
BROCADE Study
A treatment study investigating the PARP inhibitor veliparib for people with advanced breast cancer who have a BRCA 1 or BRCA 2 mutation.
INFORM Study
A study for newly-diagnosed breast cancer patients who carry a BRCA1 or BRCA2 mutation.
INVITE Study
INVITE is enrolling people who received the drug bevacizumab (also known as Avastin®) for metastatic cancer prior to 2013. Involves submitting a saliva sample.
Salpingectomy Research Registry
Study for women who have had their fallopian tubes surgically removed and kept one or both of your ovaries to reduce their ovarian cancer risk.
FORCE Research Surveys
FORCE conducts surveys to better understand and address the needs of our community. By participating, you can help advance hereditary breast and ovarian cancer research.
Basser Research Center for BRCA
Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.
BROCADE Study
Men and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation are invited to see if they may qualify for the Brocade Study to determine the safety and effectiveness of the investigational PARP inhibitor medication veliparib in combination with chemotherapy.
INFORM Study
INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited abnormality (mutation) in one of the breast cancer genes, BRCA1 or BRCA2.
INVITE Study
The InVite study is enrolling individuals who have received bevacizumab (also known as Avastin®) for metastatic cancer prior to 2013. The study has been expanded to enroll people who received Avastin for the following cancers:
-metastatic breast cancer
-metastatic colorectal cancer
-metastatic non-squamous, non-small cell lung cancer
-relapsed glioblastoma
-metastatic renal cell carcinoma
Participation is free, but you must have access to a computer and the Internet. Participants in the study will submit DNA samples via an at-home saliva collection kit and potentially a blood sample through a qualified laboratory.
Salpingectomy Research Registry
Have you had your fallopian tubes surgically removed and kept one or both of your ovaries? Did you have this surgery to reduce your ovarian cancer risk? Researchers at the University of Washington in collaboration with Facing Our Risk of Cancer Empowered (FORCE) are studying the long-term outcomes of prophylactic salpingectomy (removal of the fallopian tubes). To learn more about this research study, call 206-685-7927 or email vhy@uw.edu orkagnew@uw.edu. They cannot ensure the confidentiality of any information sent by e-mail.
FORCE Research Surveys
FORCE conducts surveys and partners with researchers who conduct surveys to better understand and address the needs of our community. By participating in surveys for which you are eligible, you help promote and advance hereditary breast and ovarian cancer research.
Basser Research Center for BRCA
Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.